-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Fourth Pharmaceutical Group Achieves a Strong Start to the First Quarter
Category:
Time：2022-04-09
Shijiazhuang Sihua Pharmaceutical Group has delivered encouraging news: In the first quarter of this year, the company’s total industrial output value and sales revenue both achieved double-digit year-on-year growth, securing a strong start to the quarter and continuing to maintain a steady development momentum.
With the arrival of spring and the brightening of the scenery, all things are thriving. In tune with the rhythm of spring, Shijiazhuang No.4 Pharmaceutical Group has delivered encouraging news: in the first quarter of this year, the company’s total industrial output value and sales revenue both achieved double-digit year-on-year growth, securing a strong start to the quarter and continuing to maintain a steady development momentum.
Stepping into the intravenous injection preparation workshop of Shijiazhuang Fourth Pharmaceutical, located in the high-tech zone’s factory premises, we find employees bustling with enthusiasm and energy. At the packaging stage, robotic arms operate intelligently, and automated equipment hums cheerfully—every corner exudes a vibrant, spring-like vitality.
“This year, we’ve firmly established the principles of ‘market first’ and ‘efficiency first,’ closely following market trends and employing flexible, diversified, and robust measures to drive the development of national and regional centralized procurement markets, clinical markets, and various end-user markets. We’re accelerating the development of untapped markets, deeply tapping into their potential, shifting our market focus downward, and making concerted efforts to capture a larger share of the grassroots healthcare market,” said Su Xuejun, Chairman of Shijiazhuang Fourth Pharmaceutical. “Last year, more than 20 newly approved drug varieties from Fourth Pharmaceutical have now entered production. Many of these new products boast compelling advantages in terms of indications, cost, and accessibility. For instance, our new product—terbutaline inhalation solution—became highly sought after as soon as it was launched this year. Sales of our newly included drugs in the national centralized procurement program also saw explosive growth in the first quarter, giving us a decisive edge in achieving a strong start to the year.”
In the first quarter, Sihua Pharmaceutical achieved a series of exciting R&D breakthroughs, receiving approval for 9 new specialty formulations and active pharmaceutical ingredients. Its R&D progress and the number of approvals it has secured rank among the industry leaders. “We are focusing on products that are most in demand and urgently needed by the market, intensifying our efforts to develop and master leading-edge new products,” said Su Xuejun. “By closely aligning our R&D activities with market trends and competitive dynamics, we’re accelerating the efficiency of new product development, approval processes, and technology transfer, thereby leveraging innovation to drive the group’s high-quality development.” Sihua Pharmaceutical is speeding up its strategic deployment in areas including antiviral, antibacterial, nervous system, anti-tumor, cardiovascular, and anesthetic therapies. Currently, the company has nearly 200 new products in various stages of development, with more than 60 awaiting regulatory approval. In the first quarter of this year alone, Sihua Pharmaceutical secured approval for 9 new products. This diversified and innovative industrial layout is providing robust momentum for Sihua Pharmaceutical to accelerate its journey toward high-quality development.
In terms of project construction, Siyao is leaving no stone unturned. At the construction site of the New Formulation and Biopharmaceutical Industrial Park belonging to Hebei Guolong Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Siyao Group located in the Shijiazhuang Economic Development Zone, several tower cranes are seen with their booms rotating overhead, while on the ground, loaders and excavators rumble away, composing a new symphony of “accelerated progress.” The entire project is now in full swing. Zhao Yongzheng, CEO of Siyao and Chairman of Guolong Pharmaceutical, said: “To ensure that the project goes into production as soon as possible, we’re working overtime, and our employees are full of energy and confidence.” Currently, Siyao has six key technological upgrade projects under construction. These projects will strongly propel the company’s transformation toward a modern, intelligent, and high-end industrial structure.
“Next, we will continue to increase our investment in innovation, accelerate the implementation of high-end industrialization projects, and make every effort to prepare for the seventh round of national centralized procurement bidding. We will also pioneer market development that is forward-looking and highly influential, striving to achieve ‘more than half’ performance in the second quarter. In doing so, we aim to help Shijiazhuang Sihua Pharmaceutical Group take the lead in breaking through barriers in the city’s biopharmaceutical industry, build a trillion-yuan-level industrial cluster, and contribute early to raising the city’s total economic output above one trillion yuan.”
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license